Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study

Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study

Show other versions (1)

<h4>Background</h4> Passive immunotherapy has been evaluated as a therapeutic alternative for patients with COVID-19 disease. Equine polyclonal immunotherapy for COVID-19 (EPIC) showed adequate safety and potential efficacy in a clinical trial setting and obtained emergency use authoriza...

Full description

Bibliographic Details
Main Authors: Diego H. Farizano Salazar, Fernando Achinelli, Mariana Colonna, Lucía Pérez, Analía A. Giménez, Maria Alejandra Ojeda, Susana N. Miranda Puente, Lía Sánchez Negrette, Florencia Cañete, Ornela I. Martelotte Ibarra, Santiago Sanguineti, Linus Spatz, Fernando A. Goldbaum, Carolina Massa, Marta Rivas, Mariana Pichel, Yanina Hiriart, Vanesa Zylberman, Sandra Gallego, Brenda Konigheim, Francisco Fernández, Matías Deprati, Ian Roubicek, Diego H. Giunta, Esteban Nannini, Gustavo Lopardo, Waldo H. Belloso
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512184/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512184/?tool=EBI

Similar Items